First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $207M — -12.4% growth in a single year.
What Moves the Stock
1Vafseo commercial performance updates in Japan - prescription trends, market share gains against competitors like Evrenzo (roxadustat) and traditional ESAs
2Regulatory developments for vadadustat in potential new markets or indications beyond Japan approval
3Partnership announcements or licensing deals that provide non-dilutive capital and validate the HIF-PHI platform
4Cash runway updates and financing activities - equity raises, debt restructuring, or strategic alternatives given negative cash flow
5Clinical data readouts or safety updates for vadadustat, particularly any differentiation versus competing HIF-PHIs
6Collaboration revenue from Mitsubishi Tanabe Pharma for Vafseo (vadadustat) in Japan - milestone payments and royalties
7Historical Auryxia product revenue (divested rights to Akebia's US commercial operations in recent restructuring)
8Potential future licensing deals or milestone payments from vadadustat development programs
speculation - Akebia attracts high-risk biotech investors and event-driven traders betting on binary outcomes (partnership announcements…
Rising interest rates negatively impact Akebia through multiple channels: (1) Higher discount rates compress the present value of future…
Watch on earnings: Quarterly collaboration revenue from Mitsubishi Tanabe and any milestone payment announcements, Cash and cash equivalents balance relative to quarterly operating cash burn rate, Vafseo prescription volume trends in Japan from third-party data sources (IQVIA, Symphony Health).
One Sentence Summary:
Akebia Therapeutics: the story is balanced — vafseo commercial performance updates in japan - prescription trends, market share gains against competitors like evrenzo (roxadustat).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.